Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced its participation in a Virtual Investor “What This Means” segment featuring Dr. Toufic Kachaamy, Chief of Medicine at City of Hope in Phoenix.
The discussion covered clinical data presented at the Society of Surgical Oncology meeting, focusing on visceral cancer pain treatment, pancreatic cancer feasibility, and broader peripheral nervous system platform potential.
Positive
- None.
Negative
- None.
News Market Reaction – AMIX
In the Jun 4 session, AMIX gained 3.57%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | ASCO GI data | Positive | +2.8% | PoC1 data showing rapid, durable pain relief in pancreatic cancer patients. |
| Aug 14 | Device design milestone | Positive | +1.8% | Final design review of intravascular nerve sensing catheter toward U.S. trials. |
| Jun 30 | PoC2 first patient | Positive | -21.9% | First patient treated in PoC2 expansion targeting broader visceral cancer pain. |
| Jun 05 | Trial expansion approval | Positive | -15.8% | Ethics approval to expand PoC study, doubling addressable visceral cancer market. |
| Mar 14 | Platform integration | Positive | -9.8% | Integration of Apex 6 RF generator into platform, supporting U.S. IDE plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical and platform milestones often saw mixed-to-negative price reactions, with several clinically positive updates followed by share price declines.
Over the past year, AMIX has repeatedly highlighted its nerve-targeted platform through clinical trial milestones and technology advances. Events such as IDE preparation, PoC study expansion, and compelling pancreatic cancer pain data (e.g., ASCO GI on Jan 9, 2026) generally described favorable clinical progress. However, several of these clinically positive announcements were followed by share price declines, suggesting a pattern where encouraging trial news did not consistently translate into sustained market strength.
Key Terms
visceral cancer pain medical
pancreatic cancer medical
peripheral nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Toufic Kachaamy Discusses Visceral Cancer Pain Treatment Differentiation, Pancreatic Cancer Feasibility Data, and Peripheral Nervous System Platform Potential
Access the segment here
THE WOODLANDS, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it recently participated in a Virtual Investor “What This Means” segment.
For the segment, Key Opinion Leader and Chief of Medicine at City of Hope in Phoenix, Dr. Toufic Kachaamy, discussed the clinical significance of data presented by Autonomix Medical at the Society of Surgical Oncology Annual Meeting (SSO), highlighting the importance of the work being selected for a podium presentation and its relevance to the surgical oncology community. The segment explored the potential clinical impact of the Company’s approach to managing visceral cancer pain, how it differs from existing treatment techniques, and why those differences may matter in practice. Dr. Kachaamy also addressed the broader applicability of the findings beyond pancreatic cancer and discussed how the results support the ongoing clinical development and feasibility of the technology platform.
The “What This Means” segment can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release and in the video include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions, the capabilities of the Company's platform technology, and the potential applicability of the technology across multiple indications.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
